Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-trans-retinoic acid.

Abstract:

:Acute promyelocytic leukemia (APL) cells express different types of procoagulant activity (PCA), including tissue factor (TF), and cancer procoagulant (CP). The aim of this study was to investigate whether the NB4 cell line, the first ever isolated human APL line, with the typical t(15;17) chromosomal balance translocation, possess CP as well as the cells freshly isolated from APL patients. Secondly, since the NB4 line is maturation inducible by all-trans-retinoic acid (ATRA), we wanted to verify whether CP, if present, was affected by ATRA treatment. The NB4 cells were able to shorten the recalcification assay of normal human plasma (total PCA). To distinguish CP in the assay for clotting activity, two criteria were used, the independence from factor VII to trigger blood coagulation and the sensitivity to cysteine proteinase inhibitors. Forty-seven per cent of total PCA of cell extracts was found to be FVII-independent PCA. A similar proportion of FVII-independent activity (42%) was detected in the cell serum-free supernatants. The activity was significantly decreased by cysteine proteinase inhibitors, including HgCl2, lodoacetic acid and Z-Ala-AlaCHN2. Additionally CP was directly identified and quantified by an immunocapture enzyme assay. The mean +/- SD concentration of CP detected by this assay in the NB4 cells, before any treatment, was 1.89 +/- 0.5 microgram/mg protein. Treatment of NB4 cells with 10(-6) M ATRA for 5 days significantly decreased the expression of CP, which became virtually undetectable by the clotting assay, and was 64% less than the untreated control by the immunocapture enzyme assay. This study provides the first evidence that the human promyelocytic cell line NB4 possess CP. The expression of this procoagulant is modulated by ATRA.

journal_name

Leukemia

journal_title

Leukemia

authors

Falanga A,Consonni R,Marchetti M,Mielicki WP,Rambaldi A,Lanotte M,Gordon SG,Barbui T

subject

Has Abstract

pub_date

1994-01-01 00:00:00

pages

156-9

issue

1

eissn

0887-6924

issn

1476-5551

journal_volume

8

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Prognostic impact of RAS-pathway mutations in patients with myelofibrosis.

    abstract::RAS-pathway mutations are recurrent events in myeloid malignancies. However, there is limited data on the significance of RAS-pathway mutations in patients with myelofibrosis (MF). We analyzed next-generation sequencing data of 16 genes, including RAS-pathway genes, from 723 patients with primary and secondary MF acro...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/s41375-019-0603-9

    authors: Santos FPS,Getta B,Masarova L,Famulare C,Schulman J,Datoguia TS,Puga RD,Alves Paiva RM,Arcila ME,Hamerschlak N,Kantarjian HM,Levine RL,Campregher PV,Rampal RK,Verstovsek S

    更新日期:2020-03-01 00:00:00

  • Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia.

    abstract::To assess the efficacy and toxicity of HAA regimen (homoharritonine 4 mg/m2/day, days 1-3; cytarabine 150 mg/m2/day, days 1-7; aclarubicin 12 mg/m2/day, days 1-7) as an induction therapy in the treatment of de novo acute myeloid leukemia (AML), 48 patients with newly diagnosed AML, aged 35 (14-57) years, were entered ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404287

    authors: Jin J,Jiang DZ,Mai WY,Meng HT,Qian WB,Tong HY,Huang J,Mao LP,Tong Y,Wang L,Chen ZM,Xu WL

    更新日期:2006-08-01 00:00:00

  • Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity.

    abstract::Some anaplastic large cell lymphomas (ALCLs) carry a specific chromosomal translocation, t(2;5)(p23;q35). Recently, we found a novel hyperphosphorylated 80-kDa protein tyrosine kinase, p80, in ALCLs with t(2;5). Subsequent cDNA cloning revealed p80 to be a fusion protein of two genes, the novel tyrosine kinase gene an...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Shiota M,Mori S

    更新日期:1997-04-01 00:00:00

  • Effect of ubenimex on the proliferation and differentiation of U937 human histiocytic lymphoma cells.

    abstract::We investigated the effect of ubenimex on the growth and differentiation of U937 cells, a histiocytic lymphoma cell line. Ubenimex is a dipeptide ((2S,3R)-3-amino-2-hydroxy-4-phenylbutyryl-L-leucine) and an inhibitor of aminopeptidase B produced by Streptomyces olivoreticuli. Ubenimex inhibited the proliferation of U9...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Murata M,Kubota Y,Tanaka T,Iida-Tanaka K,Takahara J,Irino S

    更新日期:1994-12-01 00:00:00

  • Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40.

    abstract::Event-free survival (EFS) at 5 years in pediatric acute lymphoblastic leukemia (ALL) is >80%. Outcome in adult ALL is still unsatisfactory, which is due to less cumulative dosing of chemotherapy and less strict adherence to timing of successive cycles. In the present phase II trial, we evaluated a pediatric regimen in...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2011.141

    authors: Rijneveld AW,van der Holt B,Daenen SM,Biemond BJ,de Weerdt O,Muus P,Maertens J,Mattijssen V,Demuynck H,Legdeur MC,Wijermans PW,Wittebol S,Spoelstra FM,Dekker AW,Ossenkoppele GJ,Willemze R,Cornelissen JJ,Dutch-Belgian HO

    更新日期:2011-11-01 00:00:00

  • Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.

    abstract::Treatment resistance in T-cell acute lymphoblastic leukemia (T-ALL) is associated with phosphatase and tensin homolog (PTEN) deletions and resultant phosphatidylinositol 3'-kinase (PI3K)-AKT pathway activation, as well as MYC overexpression, and these pathways repress mitochondrial apoptosis in established T-lymphobla...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2014.78

    authors: Reynolds C,Roderick JE,LaBelle JL,Bird G,Mathieu R,Bodaar K,Colon D,Pyati U,Stevenson KE,Qi J,Harris M,Silverman LB,Sallan SE,Bradner JE,Neuberg DS,Look AT,Walensky LD,Kelliher MA,Gutierrez A

    更新日期:2014-09-01 00:00:00

  • Tissue factor and plasminogen activator inhibitor expression in the differentiation of myeloid leukemic cells.

    abstract::Disturbances in the regulation of the balance between the fibrinolytic and procoagulant properties of leukemic cells may contribute to the coagulopathy of acute leukemia. The coagulant response to a number of stimuli is regulated by the expression of tissue factor, but the role of the plasminogen activator inhibitors,...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Dickinson JL,Antalis TM

    更新日期:1993-06-01 00:00:00

  • The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages.

    abstract::We previously reported a strong IL4I1 gene expression in primary mediastinal B-cell lymphoma (PMBL) and recently identified the protein as a secreted L-phenylalanine oxidase, physiologically expressed by myeloid cells, which inhibits T-cell proliferation in vitro. Here, we analyzed the pattern of IL4I1 protein express...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.380

    authors: Carbonnelle-Puscian A,Copie-Bergman C,Baia M,Martin-Garcia N,Allory Y,Haioun C,Crémades A,Abd-Alsamad I,Farcet JP,Gaulard P,Castellano F,Molinier-Frenkel V

    更新日期:2009-05-01 00:00:00

  • Detection of low abundance mRNA of myeloid specific genes in cells of acute and chronic lymphoid leukemias by cRNA hybridization.

    abstract::The hybridization to a complementary RNA (cRNA) probe both in situ and in solution was used to assay tiny amounts of mRNA of the lactoferrin (LF) and myeloperoxidase (MPO) genes in normal bone marrow cells and in acute and chronic lymphoid leukemias. Evidence is reported that this technique is much more sensitive than...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Ferrari S,Ceccherelli G,Tagliafico E,Zucchini P,Manfredini R,Torelli G,Emilia G,Torelli U

    更新日期:1990-10-01 00:00:00

  • Colony-forming unit-megakaryocyte (CFR-meg) numbers and serum thrombopoietin concentrations in thrombocytopenic disorders: an inverse correlation in myelodysplastic syndromes.

    abstract::We studied both serum-free colony-forming unit-megakaryocyte (CFU-meg) numbers and serum thrombopoietin (TPO) levels in 14 patients with aplastic anemia (AA), 37 patients with myelodysplastic syndromes (MDS) and 23 patients with idiopathic thrombocytopenic purpura (ITP) to assess thrombopoiesis in these thrombocytopen...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401898

    authors: Wang W,Matsuo T,Yoshida S,Mori H,Miyazaki Y,Kuriyama K,Tomonaga M

    更新日期:2000-10-01 00:00:00

  • JAK inhibitors suppress t(8;21) fusion protein-induced leukemia.

    abstract::Oncogenic mutations in components of the JAK/STAT pathway, including those in cytokine receptors and JAKs, lead to increased activity of downstream signaling and are frequently found in leukemia and other hematological disorders. Thus, small-molecule inhibitors of this pathway have been the focus of targeted therapy i...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.197

    authors: Lo MC,Peterson LF,Yan M,Cong X,Hickman JH,Dekelver RC,Niewerth D,Zhang DE

    更新日期:2013-12-01 00:00:00

  • Modulation of IL-8, IL-1 beta, and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia.

    abstract::Acute promyelocytic leukemia (APL) is a homogeneous subgroup of acute myeloid leukemias (AML) characterized by the presence of the t(15;17) translocation and the resulting PML/RAR alpha fusion proteins. To date APL is the only AML which is sufficiently sensitive to all-trans retinoic acid (ATRA) differentiating effect...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Dubois C,Schlageter MH,de Gentile A,Balitrand N,Toubert ME,Krawice I,Fenaux P,Castaigne S,Najean Y,Degos L

    更新日期:1994-10-01 00:00:00

  • Expression of p16INK4A and p14ARF in hematological malignancies.

    abstract::The INK4A/ARF locus yields two tumor suppressors, p16INK4A and p14ARF, and is frequently deleted in human tumors. We studied their mRNA expressions in 41 hematopoietic cell lines and in 137 patients with hematological malignancies; we used a quantitative reverse transcription-PCR assay. Normal peripheral bloods, bone ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401557

    authors: Taniguchi T,Chikatsu N,Takahashi S,Fujita A,Uchimaru K,Asano S,Fujita T,Motokura T

    更新日期:1999-11-01 00:00:00

  • International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.

    abstract::In 2005, the first guidelines were published on the management of patients with multiple myeloma (MM). An expert panel reviewed the currently available literature as the basis for a set of revised and updated consensus guidelines for the diagnosis and management of patients with MM who are not eligible for autologous ...

    journal_title:Leukemia

    pub_type: 杂志文章,实务指引,评审

    doi:10.1038/leu.2009.122

    authors: Palumbo A,Sezer O,Kyle R,Miguel JS,Orlowski RZ,Moreau P,Niesvizky R,Morgan G,Comenzo R,Sonneveld P,Kumar S,Hajek R,Giralt S,Bringhen S,Anderson KC,Richardson PG,Cavo M,Davies F,Bladé J,Einsele H,Dimopoulos MA,Sp

    更新日期:2009-10-01 00:00:00

  • Changes in peripheral blood and bone marrow specimens during and after alpha 2b-interferon therapy for hairy cell leukemia.

    abstract::We studied changes in peripheral blood and bone marrow biopsy specimens obtained before, during, and after recombinant alpha 2b-interferon (IFN-alpha 2b) therapy in 25 patients with hairy cell leukemia. During therapy, only 1 patient showed no improvement in at least one of the parameters monitored. Granulocytopenia, ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Bardawil RG,Ratain MJ,Golomb HM,Bitter MA,Groves C,Vardiman JW

    更新日期:1987-04-01 00:00:00

  • Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia Trial XI (MRC UKALLXI). Medical Research Council Childhood Leukaemia Working Party.

    abstract::Despite many years of meticulous immunophenotyping of childhood acute lymphoblastic leukaemia (ALL) cases the prognostic significance of some subtypes remains unclear. The Medical Research Council UKALLXI trial (1990-1996) in which uniform treatment has been given to 2090 children with ALL below the age of 18 years an...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1038/sj.leu.2401093

    authors: Hann IM,Richards SM,Eden OB,Hill FG

    更新日期:1998-08-01 00:00:00

  • Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features.

    abstract::Chromosomal translocations involving the MYC oncogene are a hallmark of Burkitt lymphoma but they are only found in a varying frequency in mature Burkitt-type acute lymphoblastic leukemia (B-ALL). We have investigated samples of 56 sporadic Burkitt leukemia/lymphoma patients for the translocations t(8;14)(q24;q32), t(...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403847

    authors: Burmeister T,Schwartz S,Horst HA,Rieder H,Gökbuget N,Hoelzer D,Thiel E

    更新日期:2005-08-01 00:00:00

  • A phase I trial of carboplatin and etoposide given as continuous infusions to adults with leukemia.

    abstract::Thirty-two adult patients with acute leukemia were treated with continuous infusion carboplatin and etoposide at eight different dose levels. Dose limiting toxicity was encountered at doses of carboplatin of 310 mg/m2 per day for 5 days (total 1550 mg/m2 per course) and etoposide 150 mg/m2 per day for 5 days (total do...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:

    authors: Lee EJ,Reck K,Carter C,Hodges S,Schiffer CA

    更新日期:1993-10-01 00:00:00

  • Mutational and expression analysis of the chromosome 12p candidate tumor suppressor genes in pre-B acute lymphoblastic leukemia.

    abstract::Allelic losses on chromosome 12p12-13 are associated with childhood acute lymphoblastic leukemia (ALL) and several solid neoplasias, suggesting the presence of a tumor suppressor locus. The recent construction of a transcription map of this locus has enabled the identification of eight genes, of which five were previo...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403441

    authors: Montpetit A,Larose J,Boily G,Langlois S,Trudel N,Sinnett D

    更新日期:2004-09-01 00:00:00

  • Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells.

    abstract::Lovastatin is an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the major regulatory enzyme of the mevalonate pathway. We have previously reported that lovastatin induces a significant apoptotic response in human acute myeloid leukemia (AML) cells. To identify the critical biochemic...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402196

    authors: Xia Z,Tan MM,Wong WW,Dimitroulakos J,Minden MD,Penn LZ

    更新日期:2001-09-01 00:00:00

  • The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation.

    abstract::Hematopoietic stem cell transplantation is becoming an increasingly important approach to treatment of different malignant and non-malignant disorders. There is thus growing demand for diagnostic assays permitting the surveillance of donor/recipient chimerism posttransplant. Current techniques are heterogeneous, rende...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.66

    authors: Lion T,Watzinger F,Preuner S,Kreyenberg H,Tilanus M,de Weger R,van Loon J,de Vries L,Cavé H,Acquaviva C,Lawler M,Crampe M,Serra A,Saglio B,Colnaghi F,Biondi A,van Dongen JJ,van der Burg M,Gonzalez M,Alcoceba M,Bar

    更新日期:2012-08-01 00:00:00

  • Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.

    abstract::The current study was initiated to compare the anti-lymphoma activity and side-effects of prednimustine/mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) in patients with advanced low-grade non-Hodgkin's lymphomas in way of a prospective randomized multicenter trial. Two hundred and forty-six patie...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Unterhalt M,Herrmann R,Tiemann M,Parwaresch R,Stein H,Trümper L,Nahler M,Reuss-Borst M,Tirier C,Neubauer A,Freund M,Kreuser ED,Dietzfelbinger H,Bodenstein H,Engert A,Stauder R,Eimermacher H,Landys K,Hiddemann W

    更新日期:1996-05-01 00:00:00

  • Detection of additional JH/BCL2 translocations in follicular lymphoma.

    abstract::In vitro enzymatic amplification and direct sequencing were used to detect and characterize t(14;18) recombination junctions in peripheral blood and bone marrow mononuclear cell preparations from patients with follicular lymphoma in remission. Samples from 24/44 patients were found to be positive for translocations in...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Price CG,Tuszynski A,Watt SM,Murdoch SJ,Lister TA,Young BD

    更新日期:1991-07-01 00:00:00

  • Imatinib sensitizes CLL lymphocytes to chlorambucil.

    abstract::The effect of imatinib on chlorambucil (CLB) cytotoxicity in chronic lymphocytic leukemia (CLL) lymphocytes was examined in vitro. Imatinib sensitizes the WSU and I83 human CLL cell lines, 10- and two-fold, respectively, to CLB. Furthermore, in primary cultures of malignant B-lymphocytes obtained from 12 patients with...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403247

    authors: Aloyz R,Grzywacz K,Xu ZY,Loignon M,Alaoui-Jamali MA,Panasci L

    更新日期:2004-03-01 00:00:00

  • The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.

    abstract::The three DNA methyltransferase (DNMT)-inhibiting cytosine nucleoside analogues, azacitidine, decitabine and zebularine, which are currently studied as nonintensive therapy for myelodysplastic syndromes and acute myeloid leukemia (AML), differ in structure and metabolism, suggesting that they may have differential mol...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.397

    authors: Flotho C,Claus R,Batz C,Schneider M,Sandrock I,Ihde S,Plass C,Niemeyer CM,Lübbert M

    更新日期:2009-06-01 00:00:00

  • 14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors.

    abstract::14-3-3 proteins are a family of master regulators of intracellular signaling, yet their impact on proteasome function is unknown. We demonstrate that 14-3-3ζ binds the 11S proteasome activator, limiting proteasome assembly and cellular capacity for protein degradation. To define the functional impact of 14-3-3ζ protea...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.288

    authors: Gu Y,Xu K,Torre C,Samur M,Barwick BG,Rupji M,Arora J,Neri P,Kaufman J,Nooka A,Bernal-Mizrachi L,Vertino P,Sun SY,Chen J,Munshi N,Fu H,Kowalski J,Boise LH,Lonial S

    更新日期:2018-03-01 00:00:00

  • Characterization of acute lymphoblastic leukemia of childhood by immunoglobulin and T-cell receptor gene patterns.

    abstract::Molecular biological studies of immunoglobulin (Ig) and T-cell antigen receptor (TCR) genes provide novel approaches to the identification and characterization of the acute lymphoblastic leukemias (ALL). Such studies greatly enhance our understanding of both the cells of origin in these diseases and the order of assem...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Felix CA,Poplack DG

    更新日期:1991-12-01 00:00:00

  • The PEBP2beta/CBF beta-SMMHC chimeric protein is localized both in the cell membrane and nuclear subfractions of leukemic cells carrying chromosomal inversion 16.

    abstract::The chromosomal inversion (16)(p13q22), which is associated with the M4-eosinophilia subtype of human acute myeloid leukemia, causes the fusion of two distinct genes. The polypeptide encoded by the chimeric gene, PEBP2p/CBFp-SMMHC, retains the ability to interact with, and dominantly interfere with the function of pro...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401821

    authors: Kanto S,Chiba N,Tanaka Y,Fujita S,Endo M,Kamada N,Yoshikawa K,Fukuzaki A,Orikasa S,Watanabe T,Satake M

    更新日期:2000-07-01 00:00:00

  • Molecular characterization of jumping translocations reveals spatial and temporal breakpoint heterogeneity.

    abstract::Jumping translocations (JT) are characterized by the relocalization of the same part of a donor to several recipient chromosomes. Although JT occasionally are constitutional, most are associated with hematologic malignancies. In such cases, JT usually arise during disease progression and are associated with poor progn...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401108

    authors: Andreasson P,Höglund M,Jonson T,Békàssy A,Mitelman F,Johansson B

    更新日期:1998-09-01 00:00:00

  • A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.

    abstract::The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patients with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Eight hundred and six untreated patients in the UK NCRI AML16 trial with AML/high-risk MDS (median age, 67 years; range 56-84) and norm...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.225

    authors: Burnett AK,Russell NH,Hills RK,Kell J,Nielsen OJ,Dennis M,Cahalin P,Pocock C,Ali S,Burns S,Freeman S,Milligan D,Clark RE

    更新日期:2017-02-01 00:00:00